Quit Smoking Proven Patches (Nicotine)
Brand Names: Quit Smoking Proven Patches
Methodology & AI Transparency ⓘ
Quit Smoking Proven Patches (Nicotine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary cholinergic nicotinic agonist presentation registered by Jiashen International Trade Limited, Quit Smoking Proven Patches supplies active moiety Nicotine (cross-referenced at /meds/nicotine) in 21 mg/g Patch; 21 mg (NDC 84867-013; SPL 2025-05-17).
- 2 Real-world patient consensus: Registered under RxNorm 198030-B84867013 and SPL 2025-05-17, pairing Quit Smoking Proven Patches packaging with active ingredient Nicotine.
- 3 Typical cash cost range: Dispensing cost comparison spans $123.82 mail/discount cash up to $328.12 uninsured retail (federal NADAC $1.6017).
- 4 Top reported side effects / signs: Most commonly reported Quit Smoking Proven Patches (Nicotine) tolerability events: nausea (7.4%), headache (6.5%), dizziness (4.8%).
Ask our AI Specialists anything about Quit Smoking Proven Patches (Nicotine)
Quit Smoking Proven Patches (Nicotine) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary cholinergic nicotinic agonist presentation registered by Jiashen International Trade Limited, Quit Smoking Proven Patches supplies active moiety Nicotine (cross-referenced at /meds/nicotine) in 21 mg/g Patch; 21 mg (NDC 84867-013; SPL 2025-05-17). Clinical prescribing and dispensing guidelines focus on Uses reduces withdrawal symptoms,includingnicotine craving,associated with quittingsmoking *ifyou smoke 10 orless.
The active constituent inside Quit Smoking Proven Patches—Nicotine—functions as a targeted cholinergic nicotinic agonist agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Nicotine, Quit Smoking Proven Patches (registered by Jiashen International Trade Limited, SPL 2025-05-17) specifies proprietary packaging (84867-013) and 21 mg/g Patch; 21 mg quality controls alongside a $1.6017/unit NADAC acquisition baseline.
Clinical clearance of Quit Smoking Proven Patches (Nicotine) (Cholinergic Nicotinic Agonist) relies on mixed metabolic conjugation and unchanged urinary excretion across quit smoking proven patches (nicotine) regimens with a Terminal t½ estimated at 10–23 hrs depending on renal/hepatic reserve (Quit Smoking Proven Patches (Nicotine)) half-life; patients absorbing at F ≈ 71%–83% systemic availability after standard oral Quit Smoking Proven Patches (Nicotine) administration bioavailability typically observe target onset around time to peak concentration spans 1 to 4 hrs under quit smoking proven patches (nicotine) maintenance.
FDA clinical labeling for Quit Smoking Proven Patches (Nicotine) restricts administration in documented intolerance or hypersensitivity reaction involving nicotine (cholinergic nicotinic agonist); concurrent restricted medications flagged in section 4/7 of the quit smoking proven patches (nicotine) dailymed monograph (198030-b84867013) across 21 mg/g Patch, 21 mg, 14 mg, with self-reported patient tracking dominated by nausea (7.4% of reports), headache (6.5% of reports), fatigue (5.3% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Quit Smoking Proven Patches (Nicotine) (cholinergic nicotinic agonist).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Quit Smoking Proven Patches (Nicotine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Nicotine (cholinergic nicotinic agonist)
- Concurrent restricted medications flagged in Section 4/7 of the Quit Smoking Proven Patches (Nicotine) DailyMed monograph (198030-B84867013)
Logged Side-Effect Incidence (15 Reports)
Quit Smoking Proven Patches (Nicotine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Quit Smoking Proven Patches (Nicotine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of bupropion for relapse prevention in smokers with and without a past: What a 429-Participant Study Found Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression. Journal of general internal medicine • 2004-08-15 • Randomized Controlled Trial | N = 429 | 93/100 | PMID 15242467 ↗ |
| New Insights on Cytisinicline for smoking cessation in individuals with self-reported COPD: a: What a 532-Participant Study Found Cytisinicline significantly increased quitting for smokers with and without COPD and was well tolerated. Thorax • 2026-01-15 • Phase III Randomized Trial | N = 532 | 93/100 | PMID 40962497 ↗ |
| New Insights on Smoking behavior postmyocardial infarction among ENRICHD trial participants:: What a 1,233-Participant Study Found CBT for depression without more specific attention to smoking cessation may have little overall value as a strategy for helping post-MI patients refrain from smoking. Psychosomatic medicine • 2008-10-15 • Randomized Controlled Trial | N = 1,233 | 90/100 | PMID 18842753 ↗ |
| Can This Approach Help? Inside the Latest Research on Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Females were younger (mean age: 42.9 vs. Muscle & nerve • 2026-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41517964 ↗ |
| Can This Approach Help? Inside the Latest Research on Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Modeling smoking behavior, versus dichotomized abstinence, reveals differences in predictors of treatment effects. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco • 2025-11-23 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40358028 ↗ |
Quit Smoking Proven Patches (Nicotine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.6017/unit (~$48.05/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $328.12 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $123.82 / mo | View logs ↓ |
Quit Smoking Proven Patches (Nicotine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Quit Smoking Proven Patches (Nicotine) RxNorm Concept ID | 198030-B84867013 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.6017 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $328.12 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $123.82 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Quit Smoking Proven Patches (Nicotine) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Quit Smoking Proven Patches (Nicotine) (cholinergic nicotinic agonist) monograph synthesizing RxNorm 198030-B84867013, openFDA FAERS signals, and $123.82–$328.12 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Quit Smoking Proven Patches (Nicotine) community threads and patient logs by age, biological sex, dosage, and treatment duration.